An V. D.
- Country
- Belgium
- Department
- Paediatric hemato-oncology
Research Overview
- Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Infants with Hemophilia A Without Inhibitors
- Evaluation of Chemotherapy Regimens Including Cisplatin, Cyclophosphamide, and Etoposide in Pediatric and Young Adult Ependymoma Treatment
- Phase 3 Randomized Trial of Tovorafenib Monotherapy vs. Standard Chemotherapy in Pediatric Low-Grade Glioma with RAF Alteration
Data & Insights
Has run more than one trial at 134 of 194 partner sites.
Specializations
Neuro-Oncology
Specializes in treating various types of brain tumors, with particular emphasis on medulloblastoma and ependymoma in children and young adults. Focuses on developing targeted therapeutic approaches for different molecular subtypes of brain tumors.
- High-risk medulloblastoma management
- Intracranial and spinal ependymoma treatment
- Atypical teratoid/rhabdoid tumors
Actively involved in advancing treatment protocols for rare pediatric brain malignancies.
Pediatric Gliomas
Dedicated to investigating innovative treatments for both low-grade and high-grade gliomas in pediatric populations. Special interest in RAF-altered tumors and novel therapeutic combinations.
- RAF-altered low-grade gliomas
- Post-radiation therapy protocols
- Targeted therapy approaches
Explores combination therapies including targeted agents with conventional chemotherapy.
Hematology
Conducts research in hemophilia A treatment, with particular focus on early intervention strategies for young patients. Investigates novel therapeutic approaches for bleeding disorders.
- Early-onset hemophilia management
- Pharmacokinetic profiling
- Preventive treatment strategies
Specializes in treating infants and young children with bleeding disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.